The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced melanoma, according to phase 3 trial results published in the Journal of Clinical Oncology.
Health Professionals
Amaria Highlights Phase 1 Trial of OBX-115 in Melanoma
According to Amaria, early data from the phase 1 study, including findings presented at the 2024 American Society of Clinical Oncology Annual Meeting were encouraging, as OBX-115 was shown to be well-tolerated and did not lead to any severe adverse events.
Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma
An expert explores how prognostic gene expression testing enhances risk stratification and guides personalized treatment in melanoma and squamous cell carcinoma, and also shares clinical insights and practice pearls from my experience using these tests.
A Novel Immunotherapy Strategy May Improve Melanoma Treatment
A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as macrophage receptor with collagenous structure, or MARCO. The findings showed that blocking MARCO in combination with anti-CTLA4 therapy appreciably slows tumor progression in melanoma. The findings were reported in Journal for ImmunoTherapy of Cancer.